ED-B FN expression in hematopoietic malignancies
| Entity . | Percentage ED-B FN+ vessels . | |||
|---|---|---|---|---|
| More than 90% . | 50%-90% . | 10%-50% . | Less than 10% . | |
| Low malignant B-NHL | ||||
| Plasmacytoma | 6/14 | 6/14 | 2/14 | 0/14 |
| Mantle cell lymphoma | 6/12 | 3/12 | 2/12 | 1/12 |
| Lymphocytic lymphoma (CLL) | 3/11 | 2/11 | 4/11 | 2/11 |
| Marginal zone lymphoma | 2/4 | 2/4 | 0/4 | 0/4 |
| Lymphoplasmocytic lymphoma | 2/3 | 0/3 | 1/3 | 0/3 |
| Follicular lymphoma (FL) | ||||
| FL grade 1 | 2/5 | 2/5 | 1/5 | 0/5 |
| FL grade 2 | 6/19 | 10/19 | 2/19 | 1/19 |
| High malignant B-NHL | ||||
| FL grade 3 | 6/6 | 0/6 | 0/6 | 0/6 |
| Diffuse large B-cell lymphoma (DLBCL) | 26/38 | 6/38 | 3/38 | 3/38 |
| Centroblastic | 19/22 | 3/22 | 0/22 | 0/22 |
| Centroimmunoblastic | 4/5 | 1/5 | 0/5 | 0/5 |
| Anaplastic | 2/4 | 2/4 | 0/4 | 0/4 |
| Immunoblastic | 1/1 | 0/1 | 0/1 | 0/1 |
| Plasmoblastic | 0/3 | 0/3 | 2/3 | 1/3 |
| T-cell rich | 0/3 | 0/3 | 1/3 | 2/3 |
| B-lymphoblastic lymphoma | 0/4 | 3/4 | 1/4 | 0/4 |
| T-NHL | ||||
| Anaplastic large T-cell lymphoma | 7/14 | 1/14 | 4/14 | 2/14 |
| T lymphoblastic lymphoma | 4/7 | 2/7 | 1/7 | 0/7 |
| Peripheral T-NHL (NOS) | 4/5 | 0/5 | 1/5 | 0/5 |
| Hodgkin lymphoma | ||||
| Classical Hodgkin lymphoma (cHL) | 28/50 | 13/50 | 6/50 | 3/50 |
| Mixed cellularity | 12/24 | 4/24 | 6/24 | 2/24 |
| Nodular sclerosis | 16/23 | 6/23 | 0/23 | 1/23 |
| Lymphocyte rich | 0/3 | 3/3 | 0/3 | 0/3 |
| Lymphocyte-predominant HL | 3/7 | 3/7 | 0/7 | 1/7 |
| Chronic myeloproliferative disease | ||||
| Chronic myelogenous leukemia | 0/5 | 1/5 | 2/5 | 2/5 |
| Chronic idiopathic myelofibrosis | 2/4 | 1/4 | 1/4 | 0/4 |
| Essential thrombocythemia | 0/4 | 0/4 | 2/4 | 2/4 |
| Polycythemia vera | 0/4 | 0/4 | 2/4 | 2/4 |
| Acute myeloblastic leukemia | 0/7 | 3/7 | 4/7 | 0/7 |
| Entity . | Percentage ED-B FN+ vessels . | |||
|---|---|---|---|---|
| More than 90% . | 50%-90% . | 10%-50% . | Less than 10% . | |
| Low malignant B-NHL | ||||
| Plasmacytoma | 6/14 | 6/14 | 2/14 | 0/14 |
| Mantle cell lymphoma | 6/12 | 3/12 | 2/12 | 1/12 |
| Lymphocytic lymphoma (CLL) | 3/11 | 2/11 | 4/11 | 2/11 |
| Marginal zone lymphoma | 2/4 | 2/4 | 0/4 | 0/4 |
| Lymphoplasmocytic lymphoma | 2/3 | 0/3 | 1/3 | 0/3 |
| Follicular lymphoma (FL) | ||||
| FL grade 1 | 2/5 | 2/5 | 1/5 | 0/5 |
| FL grade 2 | 6/19 | 10/19 | 2/19 | 1/19 |
| High malignant B-NHL | ||||
| FL grade 3 | 6/6 | 0/6 | 0/6 | 0/6 |
| Diffuse large B-cell lymphoma (DLBCL) | 26/38 | 6/38 | 3/38 | 3/38 |
| Centroblastic | 19/22 | 3/22 | 0/22 | 0/22 |
| Centroimmunoblastic | 4/5 | 1/5 | 0/5 | 0/5 |
| Anaplastic | 2/4 | 2/4 | 0/4 | 0/4 |
| Immunoblastic | 1/1 | 0/1 | 0/1 | 0/1 |
| Plasmoblastic | 0/3 | 0/3 | 2/3 | 1/3 |
| T-cell rich | 0/3 | 0/3 | 1/3 | 2/3 |
| B-lymphoblastic lymphoma | 0/4 | 3/4 | 1/4 | 0/4 |
| T-NHL | ||||
| Anaplastic large T-cell lymphoma | 7/14 | 1/14 | 4/14 | 2/14 |
| T lymphoblastic lymphoma | 4/7 | 2/7 | 1/7 | 0/7 |
| Peripheral T-NHL (NOS) | 4/5 | 0/5 | 1/5 | 0/5 |
| Hodgkin lymphoma | ||||
| Classical Hodgkin lymphoma (cHL) | 28/50 | 13/50 | 6/50 | 3/50 |
| Mixed cellularity | 12/24 | 4/24 | 6/24 | 2/24 |
| Nodular sclerosis | 16/23 | 6/23 | 0/23 | 1/23 |
| Lymphocyte rich | 0/3 | 3/3 | 0/3 | 0/3 |
| Lymphocyte-predominant HL | 3/7 | 3/7 | 0/7 | 1/7 |
| Chronic myeloproliferative disease | ||||
| Chronic myelogenous leukemia | 0/5 | 1/5 | 2/5 | 2/5 |
| Chronic idiopathic myelofibrosis | 2/4 | 1/4 | 1/4 | 0/4 |
| Essential thrombocythemia | 0/4 | 0/4 | 2/4 | 2/4 |
| Polycythemia vera | 0/4 | 0/4 | 2/4 | 2/4 |
| Acute myeloblastic leukemia | 0/7 | 3/7 | 4/7 | 0/7 |
Semiquantitative analysis of ED-B FN expression in lymphoid and hematopoietic tumors.